{"id":"d41683fe2135","type":"article","url":"https://hartvaat.nl/2026/02/01/shr-1918-bij-homozygote-familiaire-hypercholesterolemie/","title":"SHR-1918 bij homozygote familiaire hypercholesterolemie","title_en":"SHR-1918 for Homozygous Familial Hypercholesterolemia","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843433","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843433","authors":[],"significance":7,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/"],"congress":"","summary_en":"This nonrandomized study of SHR-1918, a fully human ANGPTL3 antibody, showed significant LDL cholesterol reduction in homozygous familial hypercholesterolemia, adding another ANGPTL3 inhibitor to the pipeline for this severe genetic disorder.","created":"2026-07-03T10:25:27Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Niet-gerandomiseerde studie naar SHR-1918, een volledig humaan monoklonaal antilichaam tegen ANGPTL3, en het effect op LDL-cholesterol bij volwassenen met homozygote familiaire hypercholesterolemie.","abstract_original":"This nonrandomized clinical trial investigates if HR-1918, a fully human monoclonal antibody targeting angiopoietinlike 3 (ANGPTL3), is associated with a reduction in low-density lipoprotein cholesterol level in adults with homozygous familial hypercholesterolemia taking stable lipid-lowering therapy."}